XAIR · Beyond Air, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Management believes these factors raise substantial doubt about the Company’s ability to meet its obligations with cash on hand and concluded that the Company will require additional funding within one year from the date these financial statements are issued. Management is confident that the efforts to arrange financing, while not assured, will enable them to meet the Company’s obligations.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jul 13, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jul 13, 2026.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net cash burn, excluding inflows from financing activities | $19.1M | fiscal year ended March 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XAIR
this stock
Beyond Air, Inc.
|
$6.05M | — | +107.3% | — | 2.4% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 7.2%
- Net QoQ
- -777 sh
- Top holder
- Balyasny Asset Management…
Performance
Raw-price comparisons begin at the captured split on Jul 13, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XAIR | +17.8% | +13.2% | — | +19.7% | — |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +17.4% | +8.7% | — | +15.8% | — |